← WEST PHARMACEUTICAL SERVICES INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | $143.6m | $150.7m | $206.9m | $241.7m | $346.2m | $661.8m | $585.9m | $593.4m | $492.7m | $493.7m | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $143.6m | $150.7m | $206.9m | $241.7m | — | — | — | — | — | — | |
| Depreciation, Depletion and Amortization | $90.7m | $96.7m | $104.4m | $103.4m | $109.1m | $122.3m | $120.6m | $137.3m | $155.4m | $171.4m | |
| Depreciation | $88.1m | $94.3m | $101.7m | $100.0m | $104.7m | $116.9m | $116.9m | $133.7m | $151.8m | $168.6m | |
| Amortization | $2.6m | $2.4m | $2.7m | $3.4m | $4.4m | $5.4m | $3.7m | $3.6m | $3.6m | $2.8m | |
| Amortization of Intangible Assets | $2.6m | $2.4m | $2.7m | $3.4m | $4.4m | $5.4m | $3.7m | $3.6m | $3.6m | $2.8m | |
| Deferred Income Tax Expense (Benefit) | $21.5m | $41.7m | $900k | $15.3m | ($5.8m) | ($42.9m) | ($30.8m) | $37.5m | ($3.5m) | ($13.7m) | |
| Share-based Payment Arrangement, Noncash Expense | $19.5m | $16.1m | $15.1m | $24.4m | $34.0m | $37.5m | $23.7m | $23.3m | $18.7m | $23.8m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $3.7m | $3.8m | $4.4m | — | — | $14.8m | $19.4m | $12.9m | $5.7m | $2.8m | |
| Share-based Payment Arrangement, Expense | $19.5m | $16.1m | $15.1m | $24.4m | $34.0m | $37.5m | $23.7m | $23.3m | $18.7m | $23.8m | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | — | — | — | $300k | $4.5m | |
| Gain (Loss) on Sale of Assets and Asset Impairment Charges | — | — | $1.1m | $1.1m | — | — | — | ($5.3m) | — | — | |
| Goodwill and Intangible Asset Impairment | — | — | — | — | — | — | — | — | — | $500k | |
| Goodwill, Impairment Loss | — | — | — | — | — | $100k | — | — | — | — | |
| Gain (Loss) on Disposition of Assets | — | — | — | $1.9m | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Property Plant Equipment | ($700k) | ($1.6m) | ($1.8m) | ($800k) | ($7.7m) | ($1.3m) | ($2.7m) | ($11.6m) | $0 | $0 | |
| Income (Loss) from Equity Method Investments | $8.2m | $9.2m | $7.6m | $8.9m | $17.4m | $20.1m | $20.7m | $17.7m | $14.7m | $14.4m | |
| Income Tax Expense (Benefit) | $54.4m | $80.9m | $41.4m | $59.0m | $72.5m | $107.2m | $114.7m | $122.3m | $107.5m | $121.6m | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $3.0m | $500k | |
| Other Nonoperating Income (Expense) | — | — | $6.7m | ($100k) | $1.2m | $3.8m | ($51.3m) | $3.0m | ($1.0m) | ($1.0m) | |
| Income (Loss) from Equity Method Investments, Net of Dividends or Distributions | $6.8m | $7.0m | $5.9m | $6.7m | $15.8m | $17.4m | $18.1m | $14.3m | $13.4m | $10.5m | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Accounts Receivable | $23.3m | $39.7m | $43.8m | $33.3m | $46.6m | $123.5m | $35.6m | ($4.0m) | $58.8m | ($6.9m) | |
| Increase (Decrease) in Inventories | $21.2m | $3.6m | $7.0m | $18.6m | $73.7m | $86.5m | $49.8m | $13.5m | ($42.0m) | $62.8m | |
| Increase (Decrease) in Accounts Payable | $6.1m | $12.6m | $400k | $25.3m | $36.6m | $16.8m | ($2.8m) | $4.4m | $2.9m | $17.9m | |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | — | $43.9m | $25.5m | $11.3m | |
| Deconsolidation, Gain (Loss), Amount | — | ($11.1m) | $0 | $0 | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | $0 | — | $1.5m | $1.4m | $4.1m | ($9.4m) | ($10.2m) | ($8.4m) | |
| Gain (Loss) on Investments | — | — | — | — | — | ($4.3m) | ($3.5m) | ($4.3m) | — | — | |
| Goodwill | $103.0m | $107.7m | $105.8m | $107.8m | $111.1m | $109.9m | $107.3m | $108.5m | $106.0m | $109.9m | |
| Nonoperating Income (Expense) | — | — | — | — | ($5.6m) | ($3.4m) | ($54.1m) | $22.0m | — | — | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | $0 | $0 | — | — | — | — | $52.2m | — | — | — | |
| Other Operating Income (Expense), Net | $100k | ($3.9m) | $4.8m | $4.9m | ($900k) | ($900k) | $600k | $0 | ($900k) | ($1.3m) | |
| Net Cash Provided by (Used in) Operating Activities | $219.4m | $263.3m | $288.6m | $367.2m | $472.5m | $584.0m | $724.0m | $776.5m | $653.4m | $754.8m | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $170.2m | $130.8m | $104.7m | $126.4m | $174.4m | $253.4m | $284.6m | $362.0m | $377.0m | $285.9m | |
| Gain (Loss) on Sale of Investments | — | — | — | — | — | $300k | — | — | — | — | |
| Payments for (Proceeds from) Other Investing Activities | ($2.8m) | ($3.2m) | ($3.9m) | ($2.4m) | $5.1m | ($2.5m) | $3.6m | $6.7m | $1.7m | $0 | |
| Net Cash Provided by (Used in) Investing Activities | ($175.8m) | ($133.6m) | ($100.8m) | ($228.0m) | ($179.5m) | ($253.1m) | ($288.2m) | ($368.7m) | ($378.7m) | ($285.9m) | |
| Cash flows from financing activities: | |||||||||||
| Repayments of Long-term Debt | $69.8m | $34.9m | $100k | $100k | $0 | $0 | $1.2m | $2.3m | $169.0m | $0 | |
| Payments for Repurchase of Common Stock | $52.2m | $74.4m | $70.8m | $83.1m | $115.5m | $137.1m | $202.8m | $438.3m | $560.9m | $134.0m | |
| Payments of Ordinary Dividends, Common Stock | $35.8m | $39.1m | $42.1m | $45.1m | $48.1m | $51.1m | $54.1m | $57.0m | $59.1m | $61.2m | |
| Dividends Payable, Current | $9.5m | $10.4m | $11.3m | $11.8m | $12.6m | $13.4m | $14.1m | $14.8m | $15.2m | $15.8m | |
| Proceeds from (Payments for) Other Financing Activities | ($300k) | ($700k) | $0 | $0 | — | — | — | ($100k) | — | — | |
| Net Cash Provided by (Used in) Financing Activities | ($113.9m) | ($109.0m) | ($80.7m) | ($36.8m) | ($137.1m) | ($168.1m) | ($293.6m) | ($459.6m) | ($622.6m) | ($185.1m) | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($1.3m) | — | ($5.6m) | ($700k) | — | — | — | — | ($21.4m) | $22.9m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($71.6m) | $32.9m | $101.5m | $101.7m | $176.4m | $147.1m | $131.7m | ($40.4m) | ($369.3m) | $306.7m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | — | $894.3m | $853.9m | $484.6m | $791.3m | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $8.6m | $8.0m | $8.4m | $8.6m | $8.1m | $8.0m | $6.6m | $6.0m | $500k | $300k | |
| Income Taxes Paid, Net | $48.1m | $31.0m | $42.0m | $47.5m | $48.4m | $171.8m | $109.7m | $90.8m | $71.4m | $125.2m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.